氯吡格雷对冠心病介入治疗患者的血栓素B2水平、血小板聚集率及预后影响  

Effects of clopidogrel on thrombotin B2 level,platelet aggregation rate and prognosis in patients with coronary heart disease treated with percutaneous coronary intervention

作　　者：乔崇[1] 柴志勇[1] 申文宇[1] 刘琳[1] 李京倡[1] QIAO Chong;CHAI Zhiyong;SHEN Wenyu;LIU Lin;LI Jingchang(Dept.of Cardiology,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院心内一科,河南南阳473000

出　　处：《华夏医学》2021年第5期36-39,共4页Acta Medicinae Sinica

基　　金：河南省科技发展计划项目(182102310184)。

摘　　要：目的:探讨氯吡格雷在冠心病介入治疗患者中的应用效果。方法:选取88例行冠心病介入治疗的患者,将其随机分成对照组和观察组。对照组44例,予以阿司匹林常规治疗;观察组44例,加用氯吡格雷。比较两组凝血功能指标、血栓素B2(TXB2)水平与血小板聚集率(MPAR)、心血管不良事件及不良反应发生情况。结果:治疗6个月后,观察组FIB高于对照组,PT、APTT短于对照组,差异有统计学意义(P<0.05);治疗6 h、12 h后,观察组的TXB2水平、MPAR低于对照组,差异有统计学意义(P<0.05);观察组心血管不良事件发生率低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氯吡格雷在冠心病介入治疗患者中具有较高的应用价值,可改善凝血功能,降低TXB2水平和MPAR,减少心血管不良事件发生。Objective:To investigate the application effects of clopidogrel on patients with coronary heart disease(CHD)treated with percutaneous coronary intervention(PCI).Methods:88 CHD patients undergoing PCI were randomized into the control group and observation group,each with 44 cases.The control group received conventional treatment of aspirin,while the observation group were treated with clopidogrel.The indexes of coagulation function,the level of thrombin B2(TXB2),the maximum platelet aggregation rate(MPAR),cardiovascular adverse events and adverse reactions were compared between the two groups.Results:After 6 months of treatment,FIB of observation group was higher than that of the control group,while PT and APTT were shorter than that of the control group,and the differences was statistically significant(P<0.05);the level of TXB2 and MPAR in the observation group were lower than those in the control group at 6 h and 12 h after treatment,and the difference was statistically significant(P<0.05);the incidence of adverse cardiovascular events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05);and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Clopidogrel has high application value in CHD patients undergoing PCI,which can improve blood coagulation function,reduce TXB2,MPAR and the occurrence of cardiovascular adverse events.

关 键 词：冠心病介入治疗 氯吡格雷 噻氯匹定 血小板聚集率 

分 类 号：R541.4[医药卫生—心血管疾病]